Skip to main content
Clinical Trials/TCTR20210303009
TCTR20210303009CompletedPhase 4

Efficacy of Sublingual administration Misoprostol 600 mcg versus 800 mcg for induced abortion in women with early pregnancy loss: A Randomized Controlled Trial

o0 sites105 target enrollmentStarted: March 3, 2021Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
o
Enrollment
105

Study Overview

Brief Summary

There was no significant difference in success rate between 2 groups, however, the 800 mcg misoprostol was higher rate of success and side effects were not different to 600 mcg group

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to N/A (No limit) (—)
Sex
Female

Inclusion Criteria

  • 18-year-old pregnant women who were below 12 weeks of gestational age and diagnosed with an early pregnancy loss with stable vital signs, closed internal cervical os, no contraindication for misoprostol, no active bleeding, no abnormal pregnancy (ectopic pregnancy, molar pregnancy) were included

Exclusion Criteria

  • Women who were not able to follow up were excluded from this study.

Investigators

Sponsor
o

Similar Trials